Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria

Pertussis is a highly contagious infectious disease of the respiratory tract caused by Bordetella pertussis. Disease is most severe in young infants. In the USA, more than half of infants with pertussis require hospitalization when younger than 6 months and more than 80% when under 2 months old.1,2 Prevention of infant pertussis is the main goal of pertussis vaccination strategies.3 Pertussis vaccination of pregnant women is safe and the most effective strategy to protect young infants against severe pertussis.4–6 The main mechanism of passive protection in young infants is transplacental transfer of maternal antibodies against pertussis toxin (PT). PT released by B. pertussis during infection is responsible for severe disease and death in infants.7–10 Maternal anti-PT antibody levels transferred to infants must be high enough at birth to maintain the capacity to neutralize toxin until infants have developed protective immunity through active childhood immunization. All acellular pertussis vaccines including those used for vaccination in pregnancy contain PT that must be inactivated by chemical or genetic inactivation. The immunogenicity of PT is affected by the inactivation method. Chemical treatment affects the protein structure of PT, unlike detoxification by genetic engineering that maintains the conformational and immunological properties of native PT.11–18 Consequently, vaccination with genetically detoxified PT (PTgen) containing vaccines induces higher levels of anti-PT-neutralizing antibodies than vaccination with chemically detoxified vaccines.19–23 Most pertussis vaccines used for vaccination in pregnancy have been chemically inactivated and are only available combined with tetanus and diphtheria (Tdapchem). A new generation recombinant pertussis booster vaccine was studied at multiple dose levels of PTgen in a phase 2 randomized-controlled trial in pregnant women in Thailand.23 Follow-up of mothers and infants at the time of birth confirmed active transplacental transfer of maternal anti-PT antibodies for all doses of recombinant pertussis vaccine that persisted at comparable or higher levels compared with Tdapchem at 2 months of age.24 We now report on safety and antibody responses to childhood vaccination with diphtheria-tetanus-whole cell pertussis (DTwP) and 13-valent pneumococcal conjugate vaccine (PCV13) in these infants until 13 months of age according to pertussis vaccine the mother received in pregnancy. Source: PIDJ Acellular Pertussis Vaccine, aP, booster vaccine, Diphtheria, genetically detoxified pertussis toxin, immunoginicity, Pertussis, pregnancy, pregnant woman, Recombinant Acellular Pertussis Vaccine, Tdap, tetanus, vaccination, vaccine Search News categories BioNet News (29) Events (8) Biotech News (60) Thailand (2) Covid-19 (2) News tags Acellular Pertussis Vaccine (5) Adolescent (3) AI (3) aP (5) Artificial Intelligence (5) biotechnology (12) booster vaccine (3) Bordetella pertussis (9) cancer (8) Cancer vaccine (5) covid-19 (22) COVID-19 vaccine (3) Diphtheria (7) DNA (3) Flu (3) genetically detoxified pertussis toxin (6) Immune Response (8) immune system (12) Immunization (5) immunoginicity (5) infectious disease (4) infectious diseases (4) maternal immunization (3) mRNA (14) mRNA Technology (7) pandemic (8) Pertussis (9) Pertussis Toxin (4) pertussis vaccine (5) PT (5) PTgen (5) respiratory diseases (4) RNA (4) SARS-CoV-2 (8) Tdap (8) tetanus (6) Tuberculosis (3) vaccination (10) vaccine (35) Vaccine Development (10) vaccines (4) Vaccine Storage (3) virus (3) Whooping Cough (8) Whoopingcough (4) Recent News Hybrid Nanocarriers Could Enable Targeted Vaccine Delivery in the Lungs January 22, 2026 The golden age of vaccine development January 19, 2026 The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union January 15, 2026 New Pertussis Vaccine Set for Implementation December 20, 2025 BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine Against Pertussis November 21, 2025 Subscribe Terms of use Privacy 2026© BioNet-Asia. All rights reserved. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok

The release as fetched from its publisher. bionet-asia.com ↗